

**EXTRACORPOREAL NEPHROLOGY GROUP MEETING (ECNG)**

[\(https://ecng.co.in/\)](https://ecng.co.in/)


**ARE SGLT2 INHIBITORS SAFE AND EFFICACIOUS IN KIDNEY  
TRANSPLANT RECIPIENTS ? THE INFINIT TRIAL**

**Fwd.by.PROF.EDWIN FERNANDO**

**HEAD OF NEPHROLOGY**

**GOVT. STANLEY MEDICAL COLLEGE,CHENNAI**

# Are SGLT2 inhibitors safe and efficacious in kidney transplant recipients? The INFINITI Trial



Double blind placebo controlled



52 kidney transplant recipients



Diabetic and non-diabetic



Randomization 1:1 to  
Dapagliflozin 10 mg vs Placebo



Mean age = 56 yrs  
Majority on tacrolimus  
Mean eGFR = 68 ml/min/1.73 m<sup>2</sup>  
57% DM, 62 % HTN, 50% on RAASi

At 12 weeks



Primary outcome

Secondary outcome



Change in SBP

Mean difference  
between groups

**-2.9 mmHg**  
(95%CI, -8.9, 3.1)



Change in mGFR

Mean difference  
between groups

**-3.49**  
ml/min/1.73 m<sup>2</sup>  
(95 CI, -6.33 to -0.64)



Sodium Handling

No change in  
proximal sodium  
handling or  
sympathetic  
activation

\*\* No difference in incidence of adverse events in both groups\*\*

**Conclusion:** Dapagliflozin does not have a significant effect on SBP at 12 weeks in KTR despite activating expected physiological pathways.

Sridhar VS, Kugathasan L, Lytvyn Y et al, Efficacy, Mechanisms, and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Recipients: INFINITI trial, CJASN 12 Dec 2025

Visual Abstract by Janany Sabescumar

[@glomerian.bkys.social](#)